Skip to main content

Spectrum: Autism Research News

topic /

Treatments

Efforts to ease the symptoms of autism are beginning to ramp up, with promising candidates in various stages of testing.

White laboratory mice isolated on orange luminous glass surface.

New evidence hints at mechanisms for ‘fever effect’ in autism

by  /  15 November 2022
The temporary easing of traits that a minority of autistic children are reported to show during or after a fever may stem from a rise in body temperature.

Beyond the bench: Mastering meaningful movement with Karen Chenausky

by  /  21 October 2022
The competitive rower-turned-researcher spoke to Spectrum about how trying out for the U.S. national rowing team and a subsequent coaching position shaped her study of speech development.
Jeremy Levin, chief executive officer of Ovid Therapeutics, stands against a bench in a lab.

What next for Angelman?

by  /  20 October 2022
A meeting in Texas reckons with the future of treatment, following two setbacks in 2020.
October 2022
A composite of many scans of mice illustrating the effectiveness of an experimental drug.

Two-drug combo blunts autism-linked pathway in brain

by  /  14 October 2022

One drug blocks mTOR signaling, and the other stops the blocker from acting anywhere in the body but the brain, lowering the potential for side effects.

Comments
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness

by  /  13 October 2022

Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.

Comments
Laura Cancedda in Iama's lab.

Building a better drug

by  /  6 October 2022

Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.

Comments
September 2022

Oxytocin lessons from autism-linked syndromes: A chat with Christian Schaaf and Ferdinand Althammer

by  /  7 September 2022

Oxytocin therapies have failed to consistently benefit autistic people, but their effects in people with two autism-linked conditions may yield new insights, experts argue.

Comments
An adult administers a medication to an infant.

Experimental drug shows promise for autism-linked syndromes

by  /  2 September 2022

The drug quells seizures in children with Dravet syndrome or Lennox-Gastaut syndrome.

Comments
A mother and child stand, dwarfed by giant alphabet blocks spelling ABA.

Applied behavior analysis and autism: Flawed application of a proven science

by  /  1 September 2022

The field of ABA needs more compassion and individualization.

Comments
August 2022
A pregnant woman and a doctor, both masked, have a conversation in an examination room.

U.K. health authority investigates epilepsy drug’s link to autism

by  /  30 August 2022

Prenatal exposure to topiramate increases a child’s autism odds, according to the study that prompted the inquiry, but experts caution that pregnant people with epilepsy have few other options for controlling seizures.

Comments

Promising preclinical results prompt Angelman therapy trial

by  /  25 August 2022

Roche’s gene therapy drug Rugonersen boosts expression of the protein missing in the syndrome in mice and monkeys, but whether it works in people remains to be seen.

Comments
A young boy puts plates on a dining table.

Yen for routine seeds anxiety in autistic children

by  /  16 August 2022

Interventions that moderate a need for ‘sameness’ may prevent anxiety traits.

Comments
An Ultragenyx employee removes materials from a lab freezer.

Angelman therapy appears safer in restarted trial

by  /  5 August 2022

Interim results from the previously paused trial suggest that doses of the experimental gene therapy drug GTX-102 are well tolerated in children with the autism-linked condition.

Comments